A comparative study of the therapeutic effect of topical finasteride with oral finasteride in patients with androgenetic alopecia .

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220901055844N1

Enrollment

Registered

2023-12-19

Start date

2024-01-10

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic alopecia. Androgenic alopecia

Interventions

Intervention group: In group A, finasteride drug in oral form will be used. In this group, finasteride 1 mg tablets will be prescribed daily for male patients and 5 mg tablets manufactured by Ati Phar

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Having androgenic alopecia grade 2 to 5 based on the Norwood Hamilton classification in men Age above 18 years Not receiving treatment for androgenic alopecia during the last 3 months Having androgenetic alopecia grade 2 to 3 according to Ludwig grading in women Menopausal women or women over 18 years of age who use IUD or TL. Informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Failure to sign the consent form. History of allergic reaction and anaphylaxis to Finasteride drug Pregnancy or trying to have a child. Individual history of infertility Active infection or any scratches and wounds in the scalp

Design outcomes

Primary

Measure	Time frame
The rate of improvement in hair growth. Timepoint: evaluating the improvement of hair loss at the beginning of the study and at the end of 3months and at the end of 6months. Method of measurement: Comparison of the effect of topical finasteride with oral finasteride in the treatment of androgenic hair loss. how to measure this variable is with a questionnaire.;Serum Dihydrotestosterone. Timepoint: At the beginning of the study and at the end of 6 months. Method of measurement: by free blood sampling from the patient at the Motahari clinic in Shiraz byuse a lab kit to measure blood Dihydrotestosterone.;Investigation of drug side effects. Timepoint: At the end of the 3rd month and the end of the 6th month. Method of measurement: At each stage, unwanted side effects, including redness, itching and symptoms of drug reaction, as well as breast tenderness, and symptoms of sexual dysfunction, are asked from the patients and recorded in the questionnaire.	—

Measure

Time frame

The rate of improvement in hair growth. Timepoint: evaluating the improvement of hair loss at the beginning of the study and at the end of 3months and at the end of 6months. Method of measurement: Comparison of the effect of topical finasteride with oral finasteride in the treatment of androgenic hair loss. how to measure this variable is with a questionnaire.;Serum Dihydrotestosterone. Timepoint: At the beginning of the study and at the end of 6 months. Method of measurement: by free blood sampling from the patient at the Motahari clinic in Shiraz byuse a lab kit to measure blood Dihydrotestosterone.;Investigation of drug side effects. Timepoint: At the end of the 3rd month and the end of the 6th month. Method of measurement: At each stage, unwanted side effects, including redness, itching and symptoms of drug reaction, as well as breast tenderness, and symptoms of sexual dysfunction, are asked from the patients and recorded in the questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Ghahartars

Shiraz University of Medical Sciences

Mehdighahartars@yahoo.com+98 917 313 9214

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026